$599

Novo Expands Ireland Manufacturing Facility; QL Biopharm Raises $72M in Series C

Two cardiometabolic-related news items have been observed: Novo Nordisk invested $505M to expand its manufacturing in Ireland (view press release), and QL Biopharm raised $72M in a Series C round (view article). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here